In this study, we explore the antitumoral effects of Wnt pathway inhibition on STS cell lines and patient-derived primary cultures using the small molecule PRI-724, which blocks CBP/β-catenin interaction and is currently in clinical trials for different cancer types but not for STS. The gene discussed is CREBBP; the disease is telomere syndrome.